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Summary
Dendritic cells (DC) are a class of bone-marrow-derived cells arising from
lympho-myeloid haematopoiesis that form an essential interface between
the innate sensing of pathogens and the activation of adaptive immunity.
This task requires a wide range of mechanisms and responses, which are
divided between three major DC subsets: plasmacytoid DC (pDC), mye-
loid/conventional DC1 (cDC1) and myeloid/conventional DC2 (cDC2).
Each DC subset develops under the control of a specific repertoire of
transcription factors involving differential levels of IRF8 and IRF4 in col-
laboration with PU.1, ID2, E2-2, ZEB2, KLF4, IKZF1 and BATF3. DC
haematopoiesis is conserved between mammalian species and is distinct
from monocyte development. Although monocytes can differentiate into
DC, especially during inflammation, most quiescent tissues contain signif-
icant resident populations of DC lineage cells. An extended range of sur-
face markers facilitates the identification of specific DC subsets although
it remains difficult to dissociate cDC2 from monocyte-derived DC in
some settings. Recent studies based on an increasing level of resolution of
phenotype and gene expression have identified pre-DC in human blood
and heterogeneity among cDC2. These advances facilitate the integration
of mouse and human immunology, support efforts to unravel human DC
function in vivo and continue to present new translational opportunities
to medicine.
Keywords: antigen presentation/processing; dendritic cell; transcriptomics.
Introduction
The initiation and control of immune responses depends
upon dendritic cells (DC), a class of bone-marrow-
derived cells found in blood, tissues and lymphoid
organs. In a broad sense, the function of DC is to bridge
the innate and adaptive immune systems. DC are innate
immune cells because they recognize and respond to
pathogen-associated and danger-associated signals, shap-
ing the acute inflammatory response. Their defining role
in adaptive immunity is to process extracellular and
intracellular proteins and to present antigens in the con-
text of MHC molecules to prime naive T cells. Previously,
DC have been characterized as universal ‘all purpose’
antigen-presenting cells, but an important aspect of the
control of immune responses, is the existence of several
different types of DC, each specialized to respond to par-
ticular pathogens and to interact with specific subsets of
T cells. This expands the flexibility of the immune system
to react appropriately to a wide range of different patho-
gens and danger signals (Fig. 1a).
The unified classification of mammalian DC
The functional and anatomical classification of DC as
‘migratory tissue DC’ or ‘lymph node resident DC’
remains useful to define context. However, comparative
gene expression studies have driven a robust classification
of DC based primarily on lineage, that correlates with the
differential expression of key transcription factors such as
interferon regulatory factors 8 and 4 (IRF8 and IRF4)
and performs well across all mammalian species.1–4 This
recognizes plasmacytoid DC (pDC) and two types of
‘conventional’ or ‘classical’ DC (cDC) corresponding to
the two subsets of myeloid DC previously defined by
CD141 and CD1c expression in humans.5–7 These DC lin-
eage cells are treated as distinct entities to monocyte-
derived cells and monocyte-derived DC (mo-DC) and
macrophage populations derived from primitive myeloid
progenitors arising in the yolk sac (Fig. 1b).
The term ‘myeloid’, introduced into human DC biol-
ogy around two decades ago,5–7 remains valid in defining
a common set of antigens found on cDC and for clarity,
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‘myeloid’ and ‘conventional’ will be used together to
describe the human DC of this class. The original mark-
ers, CD141 and CD1c have limitations as both are
induced on cDC and monocyte-derived cells in tissues
and in culture. Expression profiling has now provided a
suite of more consistent markers that perform well across
species, such as CLEC9A, CADM1, BTLA and CD26 for
CD141+ myeloid cDC1, and CD2, FceR1 and SIRPA for
CD1c+ myeloid cDC22–4 (Table 1). Additional complexity
discussed below is the emergence of subsets of cDC2 and
the realization that conventional pDC gates include mye-
loid cDC precursors that also express CD123 and
CD303.8–10
Analysis of human dendritic cells, monocytes
and macrophages
Fluorescence flow cytometry is the most commonly used
platform for identifying human DC.2–4 This has been
expanded from the analysis of blood, to single-cell sus-
pensions of tissues including skin,11–13 lung14–16 intes-
tine17 and liver of humans2,18,19 and to lymphoid
tissue3,4,20–22 fetal tissues23 and other body fluids.24
The Tenth Human Leucocyte Differentiation Antigen
workshop has recently reported a range of new antibodies
characterized on human DC populations (Table 1).25,26
Advances through cytometry by time-of-flight now enable
30–40 antigens to be analysed simultaneously, facilitating
the dissection of complex populations of leucocytes or
‘deep phenotyping’ of selected lineages. A number of com-
putational flow cytometry tools have been developed to
scale and represent high dimensional data such as Flow-
SOM, tSNE, oneSENSE2,23 and ISOMAP.10 This approach,
rather than sequential manual gating, aids the unbiased
mapping and discovery of new cell phenotypes from mul-
tiparameter data, including that generated by conventional
fluorescence flow cytometry (reviewed in ref. 27).
In recent years, transcriptomics has moved rapidly
from expression arrays of bulk populations to single cell
RNAseq.9,10 These studies provide novel surface markers,
reveal heterogeneity within subsets and identify small but
critical DC precursor populations.9,10 It is noteworthy
that such unbiased approaches support the major classifi-
cation of known populations of pDC, cDC1 and cDC2
and confirm that empirically defined markers such as
CLEC9A and CD1c are the most highly discriminatory
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Figure 1. Ontological overview and functional specialization of human dendritic cells (DC). (a) DC are often depicted as a single ‘all purpose’
cell in diagrams of T-cell differentiation but each subset is specialized to make specific responses to pathogen or danger signals. Depending on
the context, many different responses may be observed and selected principal functions of human plasmacytoid DC (pDC), conventional DC1
(cDC1) and cDC2 are depicted. (b) Ontological basis of DC, monocyte and macrophage classification. Haematopoietic stem cells (HSC) give rise
to DC and monocyte-derived cells by distinct routes marked by differences in the relative expression of interferon regulatory factor 8 (IRF8) and
IRF4 as shown in schematic bivariate plots beneath. Monocytes are IRF4/8 low but can be induced to differentiate into monocyte-derived DC
(mo-DC). Monocyte-derived macrophages are also ontologically distinct from many populations of long-lived resident macrophages derived from
early myeloid progenitors (EMP).
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according to formal computation.9,10 Using oligonu-
cleotide tags, it is also possible to combine antibody-
based phenotyping with transcriptomics.28
New models of haematopoiesis and the origin of
human DC
Dendritic cells have a finite lifespan of days to weeks after
entering the periphery and must be continually replen-
ished by haematopoiesis. The use of media containing
Flt3 ligand, stem cell factor and granulocyte–macrophage
colony-stimulating factor (GM-CSF; ‘FSG’) with murine
stromal cells such as MS5 permits the generation of pDC
and cDC1 that are easy to identify as genuine DC with
no relationship to mo-DC.29–32 It is more challenging to
distinguish between myeloid cDC2 and DC derived from
monocytes, that form naturally in these cultures, but
retention of CD14 has been used as a de facto marker of
likely monocyte origin.9,10,32
Recent conceptual revolutions in haematopoiesis have
had a profound impact upon models of DC ontogeny.
First, the existence of a hierarchy of multipotent progeni-
tors that make a series of dichotomous fate decisions
(Fig. 2a), has been replaced by the notion that each pro-
genitor follows a predestined pathway according to lin-
eage priming that occurs at early stages in development
(Fig. 2b). In experimental terms, this means that a phe-
notypically defined population does not contain a homo-
geneous population of multi-potent cells, but rather, a
cross-section of cells primed by related but distinct devel-
opmental pathways that share a common, transient phe-
notype.33–36 Entities such as the macrophage–dendritic
cell progenitor (MDP) and common dendritic cell pro-
genitor (CDP) are evanescent. Although bi-potential and
tri-potential cells exist, profiling of > 2000 clonal outputs
from the entire range of human progenitors does not find
any significant populations corresponding to human
MDP or CDP.32 Regions thought to contain such multi-
Table 1. Human dendritic cell subset characterization
Unified classification Differential TFs Conventional markers Extended markers Notes
Plasmacytoid DC E2-2 CD123, FCER1 DC6 [9]
ZEB2 CD303/CLEC4C/BDCA-2 ILT3, ILT7
IRF8 CD304/NRP1/BDCA-4 DR6
IRF4
Myeloid cDC1 ID2 CD141/BDCA-1 CLEC9A DC1 [9]
IRF8 CADM1 No antibody for XCR1 in human
BATF3 XCR1
BTLA
CD26
DNAM-1/CD226
Myeloid cDC2 ID2 CD1c/BDCA-1 CD2 DC2/DC3 [9]
ZEB2 CD11c FCER1 DCIR clone specific [26]
IRF4 CD11b SIRPA
Notch2/KLF4 ILT1
DCIR/CLEC4A
CLEC10A
Langerhans cell ID2 CD207 EpCAM
RUNX3 CD1a TROP2
E-Cadherin
Pre-DC ZEB2 CD123, CD303 AXL DC5 ‘AS’ DC [9]
IRF4 SIGLEC 6
KLF4 CX3CR1
CD169 (SIGLEC 1)
CD22 (SIGLEC 2)
CD33 (SIGLEC 3)
Mo-DC MAFB CD11c SIRPA
KLF4 CD1c/BDCA-1 S100A8/A9
CD1a CD206
DC-SIGN/CD209
Non-classical monocyte CD16 DC4 [9]
CX3CR1 SLAN DC?
+/-SLAN
cDC, conventional DC; DC, dendritic cell; Mo-DC, monocyte-derived DC; pDC, plasmacytoid DC; TF, transcription factor. IRF4 and IRF8 are
highlighted in bold.
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potent cells mostly comprise phenotypically related cells
with a single potential.
Second, the classical dichotomy between lymphoid and
myeloid lineages, placed at the apex of haematopoiesis,
has been thoroughly revised. Common myeloid progeni-
tors are mixtures of mega-erythroid and myeloid precur-
sors and the most significant early partitioning of cell fate
occurs when megakaryocyte and erythroid potentials sep-
arate from lympho-myeloid potential.33,34,37 In contem-
porary models, lymphoid-primed multipotent progenitors
are at the apex of all myeloid and lymphoid lineages.34,36
The important consequence of this is that it is no longer
necessary to puzzle over the apparent ‘dual’ lymphoid
and myeloid origin of DC, because DC are a product of
the core lympho-myeloid pathway in which both traits
may be expressed by emerging progeny.
Hence pDC, cDC1 and cDC2 potential can be traced
through all the previously defined human progenitor
compartments from haematopoietic stem cells, through
lymphoid-primed multipotent progenitors to portions of
the granulocyte macrophage DC progenitor (GMDP) with
either high CD115 expression (MDP-like) or high CD123
expression (CDP-like) that contain mainly uni-potent
progenitors for each DC lineage32 (Fig. 3). Where DC are
derived from two different regions of the CD34+ com-
partment, they emerge transcriptionally homogeneous,
illustrating the importance of intrinsic regulatory circuits
in defining lineage and the limitations of phenotyping in
identifying discrete potentials.31
Another aspect of the lympho-myeloid model of hae-
matopoiesis is that DC can be ordered in a spectrum of
phenotypes from lymphoid to myelo-monocytic that mir-
rors their dominant developmental pathway.32 It has been
known for many years that pDC are most ‘lymphoid’
harbouring RAG and rearranged IgH loci38,39 and
expressing many markers that are distinct from
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Figure 2. Classical and revised models of human haematopoiesis. (a) In classical models of haematopoiesis, cell potential partitions by successive
bifurcations descending from the apex where common lymphoid and common myeloid progenitors (CLP; CMP) arise from the haematopietic
stem cell (HSC). Each progenitor population has homogeneous differentiation potential such that every cell has an equal probability of two
mutually exclusive fates. Hence, dendritic cells (DC) were proposed to arise in the sequence: CMPs, granulocyte–macrophage DC progenitor
(GMDP), macrophage DC progenitor (MDP), common DC progenitor (CDP) with a final pre-DC stage leading to conventional DC1 (cDC1)
and cDC2. Each population is given a uniform colour to indicate homogeneous potential. (b) Experimental data support several revisions to the
classical model. First lineage is primed in early progenitors so that most populations contain only cells with a single potential. Second, lymphoid
and myeloid potential run together originating as the lymphoid primed multi-potent progenitor (LMPP) that separates from megakaryocyte and
erythroid potential (MkE) at the apex. Hence the gates defined by CD38 (blue borders) and CD45RA (red borders) contain phenotypically
related cells but with restricted potentials, indicated by bands of colour each corresponding to a discrete lineage.
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monocytes. Myeloid cDC1 still express a mixture of
unique markers that separate them from monocytes in
addition to myeloid antigens that connect them with
myeloid lineages. At the other end of the spectrum, mye-
loid cDC2 share the most markers with monocytes and
can be difficult to dissociate entirely from mo-DC.
Human pre-dendritic cells and AXL+SIGLEC6+ DC
Between CD34+ progenitors and mature DC, there exist
potential pre-DC defined as DC-restricted precursors that
do not yet express the full phenotype of mature DC. Sev-
eral groups have reported human pre-DC that fulfil these
criteria although it is not yet completely clear how they
relate to one another. Breton and colleagues focused on
CD34-negative myeloid cDC precursors, excluding pDC
with CD123 and CD303, cDC1 with CD141 and cDC2
with CD1c40 before selecting cells with expression of the
growth factor receptors CD117 (c-kit), CD116 (GM-CSF
receptor) and CD135 (Flt-3). Other investigators have
found more numerous populations that fit the definition
of pre-DC by examining every lineage-negative HLA-DR-
positive cell using single-cell transcriptomics9 or a combi-
nation of deep phenotyping and single-cell trancrip-
tomics.10 The critical advantage of these recent studies is
that they did not begin by excluding mature DC and so
found many pre-DC among the CD123+ populations that
had been excluded as mature pDC by Breton and col-
leagues. CD123 has long been used as a marker to iden-
tify pDC but both new studies emphasize the critical
point that myeloid cDC-like cells are also captured in
CD123+ populations (Fig. 3). Moreover, the inadvertent
inclusion of these cells has confounded many previous
studies of pDC and explains the observations that pDC
can apparently differentiate into myeloid cDC in vitro.41
A re-interpretation of these results would suggest that
in vitro culture causes short-lived mature pDC to decline,
while differentiating myeloid cDC come to dominate the
preparation. This conclusion had been anticipated to a
degree by a number of reports describing subsets of
CD123+ pDC marked by CD2 or CD56 that show mye-
loid DC characteristics of inferior type I interferon pro-
duction, higher interleukin-12 (IL-12) production and
greater allo-stimulatory capacity.42–46
CD303/CLEC4C and CD304/NRP1 overlap in expres-
sion between the myeloid cDC precursor component and
pDC and cannot be used to separate the two populations
completely, although the highest expressing cells will
include only pDC.9 The non-pDC cells begin to express
myeloid cDC antigens such as CD11c, CD33 (SIGLEC 3)
and CX3CR1.10 AXL and SIGLEC 6 (CD327) emerge as
particularly useful, leading Villani and colleagues to define
a new ‘AS’ DC subset (DC5 in their classification)
(Table 1). In favour of AS DC being a distinct functional
CD123+
Bone marrow Blood
CD34+ CD34–
CD38+
CD45RA+
CD34+
pDC
cDC2
cDC1
CD123++
CD303+
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CD100+
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Figure 3. Segregation of human dendritic cell (DC) potential in late precursor compartments. The CD34+ CD38+ CD45RA+ human granulo-
cyte–macrophage DC progenitor (GMDP) contains only a minority of progenitor cells with bi- or tri-potential indicated in yellow and red,
respectively in the diagrams of cell potential of several hundred individual progenitors differentiated in vitro (schematic redrawn from data of Lee
et al.32). A small minority of progenitors in the GMDP qualify as MDP [except without plasmacytoid DC (pDC) potential] or common DC pro-
genitor (CDP; all three DC potentials). The CD123+ fraction of GMDP has been described as a CDP; although it does not contain monocyte
potential, trilineage common DC progenitors are not found in this gate. In the blood, a CD34+ CD123 precursor fraction is found to contain
conventional DC1 (cDC1) and cDC2 potential9 together with a CD34– CD123+ AXL+ SIGLEC6+ pre-DC with mainly cDC2 potential.9,10 Traces
of cDC1 potential are also found in CD123+ cells. It is not known how the CD34+ CD123 blood precursor relates to GMDP, if it is a physio-
logical route of cDC differentiation, or whether this occurs via AXL+ precursors. Broken lines indicate unconfirmed relationships.
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entity they stimulate T cells vigorously and are found in
lymphoid tissue. As potential pre-DC, the authors note
that they ‘exist in a continuum of states in vivo with the
potential to transition towards cDC2’.9 Intrinsic DC func-
tion or precursor status are not mutually exclusive roles
and AS DC may be immediately recruited for function by
some stimuli or undergo maturation to cDC2 in response
to others (as yet to be defined). See et al.10 prefer to char-
acterize a population containing AXL+ SIGLEC6+ cells
primarily as precursors, describing them as ‘early pre-DC’
with the ability to develop into cDC1 and cDC2. In sup-
port of this, See et al. observe that the ratio of cDC1:
cDC2 production by their pre-DC is in proportion with
that of mature cells in the blood. Taking a slightly wider
population of CD33+ CD45RA+ CD123+ cells, these
authors also describe lineage priming in pre-DC beginning
to express CADM1 (pre-cDC1) and CD1c (pre-cDC2).
By further relaxing the gating to include CD34+ cells,
Villani and colleagues identified another DC-restricted pre-
cursor in human blood described as CD34+ CD100+
(Fig. 3). Intriguingly, this cell has lower expression of
CD123 than AXL+ SIGLEC 6+ pre-cDC and appears to be
more primitive, owing to its lack of CD116 (GM-CSF
receptor) and higher proliferative capacity.9 It has approxi-
mately equal cDC1 and cDC2 potential in vitro and has
the highest enrichment of pre-cDC1 potential in human
blood so far described. CD34+ CD100+ cells potentially
emerge directly from a compartment of the GMDP but
further experiments will be required to test this and also to
map any relationship with the AXL+ pre-cDC.
Plasmacytoid dendritic cells
Phenotype and distribution
Plasmacytoid dendritic cells have an eccentric nucleus
and prominent endoplasmic reticulum and golgi (resem-
bling a plasma cell) for the production of type I inter-
feron (Fig. 4a). They were first identified in human blood
and tonsil.41,47,48 Unlike myeloid cDC, they do not
express the myeloid antigens CD11c, CD33, CD11b or
CD13.5,6,49 They retain expression of the GMDP markers
CD123 (IL-3R) and CD45RA, which are down-regulated
when DC progenitors differentiate into myeloid cDC.
Like all human DC they express CD4, at a higher level
than myeloid cDC.50 In addition, pDC have an array of
surface receptors that are intimately involved in the regu-
lation of their major physiological function, the produc-
tion of type I interferon. These include the well-known
human pDC markers CD303 (CLEC4C; BDCA-2), CD304
(neuropilin; BDCA-4) CD85k (ILT3) and CD85g (ILT7)
together with more recently characterized antigens FceR1,
BTLA, DR6 (TNFRSF21/CD358) and CD300A.51,52 Tran-
sciptional profiling has also added the markers FAM129C,
CUX2 and GZMB.3 Several recent papers have described
a small subset of CD123+ pDC that express CD2+,42,43
CD56+44,45 or CD5.46 These cells have a distinct gene
expression pattern that overlaps with myeloid cDC and
are now known to contain AXL+ SIGLEC 6+ myeloid
pre-cDC as described above. The two populations do not
completely overlap; some AXL-negative pDC appear to
express CD2 or CD543,46 and CD56 cannot be evaluated
in the single-cell studies because it was excluded in lin-
eage. However, studies seeking to define the characteris-
tics of ‘pure’ pDC should exclude contamination with
myeloid pre-DC using AXL and other markers.9,10
Development
Dendritic cell development in mammals is dependent on
the coordinated action of many transcription factors that
facilitate lympho-myeloid differentiation including
GATA2, PU.1, GFI1, IKZF1 and IRF853–57 (reviewed in
refs. 58–60). Heterozygous GATA2 mutation and bi-allelic
IRF8 mutation abrogate pDC development in humans.61,62
Humans with an IKZF1 mutation have a selective pDC
deficiency EcDC1 production.63
A key axis in regulating the balance of pDC and myeloid
cDC development is the antagonism between ID2, an inhi-
bitor of DNA binding, and E2-2, a basic hemophagocytic
lymphohistiocytosis protein.58,60 E2-2 is a lineage-deter-
mining factor for pDC that is negatively regulated by
ID2.64 Several recent reports describe transcription factors
that influence the relative production of pDC and cDC,
through interaction with this axis. The ETO family protein
MTG16 and the transcription factor ZEB2 are reported to
repress ID2, so increasing pDC production,65–67 while
NFIL3 acts to reduce pDC in favour of cDC1 production.68
Exogenous growth factors GM-CSF (acting through
STAT5) and Flt3L (acting through STAT3) respectively
inhibit or enhance pDC development by modulating the
expression of ID2 and E2-2. SPIB and BCL11A also posi-
tively regulate the pDC lineage through early commitment
and enhanced survival. Downstream targets of E2-2 include
SPIB and BCL11A, so stabilizing the lineage through posi-
tive feedback. E2-2 also promotes many factors critical to
the function of pDC including IRF7 and IRF8, RUNX2
and CIITA (reviewed in refs. 58–60). In humans, heterozy-
gous mutation or loss of E2-2 causes Pitt–Hopkins syn-
drome in which mature interferon-a (IFN-a)-secreting
pDC are reduced in number. Accurate exclusion of pre-
cDC in the analysis of this syndrome reveals a greater pDC
deficiency than previously suspected,10 although this does
not cause overt immunodeficiency.
Functions and role in immunity
Plasmacytoid DC are specialized to sense and respond to
viral infection through several mechanisms by the rapid
production of high quantities of type I and type III
ª 2018 The Authors. Immunology Published by John Wiley & Sons Ltd., Immunology6
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interferons and secretion of cytokines.52,59 Toll-like recep-
tor 7 (TLR7) and TLR9 are the key endosomal pattern
recognition receptors that sense single-stranded RNA and
double-stranded DNA, respectively.52 STING has also
been reported as playing a role in DNA sensing.69
Depending upon the nature of the nucleic acid cargo and
mode of delivery, interferon and cytokine production
may be differentially regulated.70 IRF7 is the major trans-
ducer of type I interferon production in pDC,71 whereas
production of tumour necrosis factor and IL-6 is depen-
dent upon the nuclear factor-jB pathway. Many other
signalling molecules participate in and regulate this pro-
cess including MyD88 and DOCK2 (reviewed in refs.
52,59).
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Figure 4. Features of the principal human
dendritic cell (DC) subsets. Diagrams of the
main surface markers, pathogen sensors and
responses of (a) plasmacytoid DC (pDC); (b)
conventional DC1 (cDC1) and (c) cDC2. Data
are principally drawn from observations on
freshly isolated blood DC and do not capture
the full range of responses possible following
inflammatory activation.
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Ligation of surface receptors modulates activation or
tolerance through the regulation of the IRF7 and nuclear
factor-jB pathways. CD300A transmits enhancing signals
through an ITIM domain51 while ligation of FceR1, ILT7
and CD303 (BDCA2) inhibits IFN-a production via
ITAM signalling (reviewed in ref. 52). Death Receptor 6
(DR6; TNFRSF21/CD358) is a specific marker of human
pDC and knock-down in pDC cell lines impairs IRF7
translocation to the nucleus.72 Sphingosine-1-phosphate
signalling interacts with ILT7 to limit TLR-induced inter-
feron production73 and with IFNAR to terminate the
IFN-a response.74
The importance of IRF7 in regulating IFN-a produc-
tion in humans was underscored by the severe suscepti-
bility to influenza and demonstrable lack of IFN-a
production by pDC in a patient with compound
heterozygous IRF7 mutation.75 Deficiency of MyD88 and
IRAK4 are predicted to affect pDC whereas DOCK8 defi-
ciency is known to be associated with decreased pDC
number and function.76 In addition to acute viral infec-
tion, pDC have been studied in chronic infections. Early
production of IFN-a by gut pDC appears to be beneficial
in HIV elite controllers77 but in chronic hepatitis, persis-
tence may be promoted by attenuated pDC responses and
pDC-mediated induction of T-cell tolerance.78,79 There is
scope for more detailed analysis of the role of pDC in
viral infections and even more so for bacterial and fungal
pathogens. The prominent role of type I interferon pro-
duction and signalling and potential of pDC to sense self-
nucleic acids80 have implicated pDC in the pathogenesis
of psoriasis,81 systemic lupus erythematosus82 and other
autoimmune diseases. Many potential therapeutic targets
are presented by the factors that modulate IFN-a release
by pDC.
Direct targeting of antigens to pDC through CD303
(CLEC4C; BDCA-2)49 or CD367 (CLEC4A, DCIR)83,84
suggests that pDC are capable of priming CD4 T cells. In
vitro experiments have also measured cross-presentation
to CD8 T cells.85,86 However, some pDC preparations
used in functional studies may have been contaminated
with myeloid cDC precursors with superior ability to pro-
cess and present antigens to T cells9,10 and further evalua-
tions of the antigen-presenting capacity of pDC are
warranted.
Conflicting roles for pDC have been reported in
allergy.87,88 Tolerogenic pDC under the influence of GM-
CSF have also been proposed to contribute to tumour
progression.89
IRF8/BATF3-dependent myeloid cDC1
Phenotype and distribution
Human myeloid cDC1 are present at approximately one-
tenth the frequency of cDC2 in steady-state blood and
tissues.2–4,7,12 They were originally described as a subset
of blood DC with high expression of CD141+ (BDCA-3,
thrombomodulin)5,6 (Fig. 4b). In common with myeloid
cDC2, they express CD13 and CD33, but differ by low
CD11c and little CD11b or SIRPa (CD172). Care must be
taken not to exclude them by selecting myeloid cDC with
only high CD11c expression. CD141 alone is not a reli-
able marker because monocytes and CD1c+ cDC2 acquire
a moderate level of expression in tissues and in vitro.12,90
(c)
CCR2 ILT1
IL-12
CD62L
IL-10
CX3CR1
CD1c
CD1a*
CD11b
CD11cCD2
FceR1SIRPA
CD1c
CD5
HLA-DQ
DC-like Mono-like
CD14
CD36
CD163
VCAN
Langerin*
*inducible
DCIR/CLEC4A
CLEC10A
CLEC6A, CLEC7A*
IL-23IL-1
IL-8
STING
TLR
9
DNA
CpG
TLR8
ssRNA Base
analogues
MHC class II
TLR5
TLR4
TLR2/6
LPS
Lipoproteins
zymosan
flagellin
TAP
MHC class I
Endosomal
cargo
IRF7IRF5
TNF-α
Subset markers
cDC2
Figure 4. (continued).
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Other markers should be used for confirmation: CLEC9A,
the receptor for actin exposed during cell necrosis,91,92
the cell adhesion molecule CADM1 (NECL2) and the
antigen BTLA considerably increase the accuracy of iden-
tification. Indoleamine 2,3-dioxygenase is also highly
expressed.3 Lack of expression of monocyte and cDC2
markers such as CD14, CD11b and SIRPa is also impor-
tant. XCR1 is also a conserved marker in many species,
as identified by several gene expression studies.93 Mono-
clonal antibodies have been harder to develop because the
structure is highly conserved, but hybrid cytokine-Fc
reagents have been successfully used.2 Intracellular detec-
tion of IRF8 may be considered a reference standard for
identifying this lineage because unopposed expression of
IRF8 (without IRF4) defines the lineage.2 However, intra-
cellular staining prevents many subsequent transcriptomic
and functional tests from being performed.
Human cDC1 are found in blood and among resident
DC of lymph node, tonsil, spleen and bone mar-
row3,4,20,29,94,95 and non-lymphoid tissues, skin, lung,
intestine and liver.2–4,12,14–19 There are suggestions that
they are more enriched in tissues than in the blood,
although this has not always been backed up by suffi-
ciently accurate characterization.
Development
Myeloid cDC1 development is dependent upon GATA2,
PU.1, GFI1, Id2, IRF8 and Basic leucine zipper transcrip-
tion factor (BATF3)53–56,96–98 (reviewed in refs. 58 and
60). IKZF1 deficiency in humans ablates pDC but results
in an increase in cDC1.63 IRF8 acts to preserve DC
potential at several points in haematopoiesis by direct or
indirect competition with a series of transcription factors
that promote other lineages: (i) IRF8 limits CEBPA-
mediated granulocytic differentiation; (ii) with PU.1 it
interacts with KLF4 to modulate the balance of DC to
monocyte differentiation; (iii) it competes with IRF4 to
control cDC1:cDC2 output and; (iv) a BATF3 ‘switch’
ensures that unopposed IRF8 maintains cDC1 matura-
tion.99 Gene dosage is a critical determinant in under-
standing the effect of IRF8 variants upon DC
development. This has been thoroughly explored in the
mouse through targeted hemizygous and homozygous
deletion100 but becomes even more complex when amino
acid substitutions are considered, as in human examples
of IRF8 variation.61,62 Generally speaking, more severe
losses of IRF8 activity incur earlier defects in haematopoi-
esis. Hence homozygous deletion causes excess produc-
tion of neutrophils and loss of monocytes and all DC.61,62
At the other extreme, subtle losses of IRF8 activity may
only affect the production of cDC1, as documented in
BXH2 mice carrying the IRF8 hypomorphic allele R294C
and IRF8 hemizygous mice.100,101 Other lineages are also
affected by IRF8 mutation including B cells and natural
killer cells, and human phenotypes show variant-specific
idiosyncracies.61,62,102 IRF8 is expressed at a low level in
haematopoietic stem cells and early progenitors. It has
been suggested that the ratio of IRF8 to PU.1 determines
DC lineage potential from primitive stages of haemato-
poiesis.32 The multi-level regulation of DC-poiesis by
IRF8, in concert with interferon-mediated signalling and
other pathways such as wnt/b-catenin and notch, is likely
to modulate cellular output during inflammatory
stress.103 In humans, short hairpin RNA knock-down of
BATF3 prevents cDC1 maturation in vitro.104 Immune
activation of other BATFs is able to bypass BATF3 defi-
ciency in mice, suggesting another pathway in which
inflammation may increase the flux of cDC1 develop-
ment.105
Functions and role in immunity
Myeloid cDC1 have been characterized as a subset of DC
that have a high intrinsic capacity to cross-present anti-
gens via MHC class I to activate CD8+ T cells and to pro-
mote T helper type 1 (Th1) and natural killer responses
through IL-12.12,29,94,106 Cross-presenting capacity per se
is less restricted to the cDC1 subset in humans than in
mouse,20,21,107–109 as reflected by lower enrichment for
MHC class I presentation pathway genes than in murine
cDC1.110,111
Human cDC1 secrete surprisingly low IL-12 compared
with appropriately activated cDC2 or mo-DC.12,20,107 This
has been a subject of some controversy but is in line with
the observation that human cDC2 and mo-DC also have
significant ability to interact and present antigens to Th1
cells.107,109,112 It appears that both cross-presentation to
CD8+ T cells and Th1 activation are less restricted to the
cDC1 lineage in humans than in mice.
These differences aside, human cDC1 possess several
conserved mechanisms that mediate efficient recognition
of viral and intracellular antigens, transport of antigen to
the appropriate endosomal compartments108 and produc-
tion of type III interferon. They are also intrinsically
resistant to productive viral infection.113 CLEC9A, a key
marker of cDC1, is a unique receptor that recognizes bare
actin filaments exposed upon necrotic cell death91,92 and
directs cell-associated antigens into the cross-presentation
pathway.114,115 Myeloid cDC1 express TLR3, TLR9 and
TLR10 and among DC, TRL3 and TLR10 are selectively
expressed.9,116,117 TLR3 plays an important role in the
recognition of dsRNA and production of type I interfer-
ons via IRF3.118 Defects in the TLR3/IRF3 axis in humans
are associated with specific susceptibility to HSV1
encephalitis through attenuated responses to viral RNA,
although not necessarily uniquely mediated by cDC1.119
TLR9 is less well studied in cDC1 but is potentially also
important in interferon responses to DNA, as in pDC.
Myeloid cDC1 are also major producers of type III
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interferons IFNk1–3120 and their accumulation in hepati-
tis C virus infection has been linked to the beneficial role
of type III interferon in viral clearance.18
Expression of the XCR1 chemokine receptor is another
conserved feature of cDC1 that enables close interaction
with XCL-producing activated T cells and natural killer
cells. Several recent studies indicate the importance of this
axis in coordinating peripheral Th1 and cytotoxic
responses121,122 in reciprocity with the action of DC-
derived CXCL9/10 upon activated T cells.123
In mice, cDC1 have also been characterized as cross-
priming tolerogenic cells but this potential is not well
documented in humans.124,125 In this respect, the
restricted expression of TLR10 by cDC1 is intriguing. It
has no known ligand and no mouse homologue but has
recently been shown to be a negative regulator of TLR
signalling.126 CD141 is also thought to transmit negative
regulation.127
IRF4/KLF4/NOTCH2-dependent myeloid cDC2
Phenotype and distribution
The major population of myeloid cDC in human blood,
tissues and lymphoid organs are characterized as myeloid
cDC2 expressing CD1c, CD2, FceR1, SIRPA and the mye-
loid antigens CD11b, CD11c, CD13 and CD33 (Fig. 4c).
Recent transcriptional profiling has identified CLEC10A
(CD301a), VEGFA and FCGR2A (CD32A) as consistent
cDC2 markers, together with the lack of cDC1 markers.3
In tissues, dermal cDC2 were first characterized as migra-
tory CD1a+ CD1c+ DC.128,129 CD1a is easily acquired by
cDC2 but neither CD1a nor CD1c are completely
restricted to cDC2 and may be expressed by cDC1 and
mo-DC isolated from tissues or in culture.12,130
In the skin, cDC2 may be distinguished from Langerhans
cells (LC) by higher CD11c and CD11b but lower CD1a,
Langerin and EpCAM.22,131 Notably, tissue cDC2 sponta-
neously express low langerin,22,131,132 in contrast to mouse
in which cDC1 express langerin. Furthermore, blood cDC2
can be induced to express high langerin and Birbeck gran-
ules in response to transforming growth factor-b (TGF-b)
in vitro133,134 although it remains unknown whether cDC2
have any potential to form LC in vivo. Myeloid cDC2 have
also been described in the lung,14–16 intestine17 and liver of
humans.2,4,19 In the lymph node, most interdigitating cells
of the T-cell areas have a phenotype compatible with cDC2
lineage.3,4,21,135–137 Tonsil and spleen also contain CD1c+
DC.20,29,138 As these tissues do not receive afferent lymph,
it is concluded that some CD1c+ DC are ‘resident DC’ orig-
inating directly from the blood.
Detailed phenotyping and single-cell gene expression
studies have recently characterized two subsets of cDC2 in
human blood, one ‘DC-like’ with higher expression of
CD5, CD1c, HLA-DQ and IRF4 and the other more
‘monocyte-like’ showing CD14, CD32, CD36, CD163 and
proportionately higher MAFB expression.8,9 CD14+ CD1c+
cells have previously been detected and characterized as
CD1c+ monocytes139 but by gene expression, most cluster
with cDC2.8,9 In tissues, especially during inflammation,
and in humans affected by cancer, it is relatively easy to
detect dual positive CD1c+ CD14+ cells12,13,140 but the ori-
gin of these may be difficult to ascertain precisely because
as mo-DC, they converge towards the monocyte-like cDC2
phenotype.30,141 Antibodies to CD2, CD5, FceR1, CLEC4A
(DCIR/CD367) and CLEC10A (CD301) may be useful but
are still inducible and labile in inflammation.
Development
Myeloid cDC2 are dependent on GATA2, PU.1, GFI1, ID2,
ZEB2, RELB, IRF4, NOTCH2 and KLF4, but unlike pDC
and cDC1, no single transcription factor has exclusive con-
trol over their development.53,60,66,142 In mice, ZEB2 has
recently been identified as a factor influencing the fate of
pre-DC towards the cDC2 lineage66 and IRF4 is considered
to be a lineage-defining factor.2 Depending upon the tissue
site, subsets of murine IRF4+ cDC2 show variable depen-
dence upon RELB, NOTCH2/RBPJ and lymphotoxin-b or a
requirement for KLF4.60 In humans, much less is known
about the differential regulation of cDC2 production.
Heterozygous GATA2 deficiency leads to eventual loss of all
cDC2.53 Bi-allelic IRF8 deficiency also abrogates cDC2 devel-
opment because the entire monocyte-DC tract of lympho-
myeloid development is lost.61,62 In contrast, cDC2 are
IRF8-independent in mice,100 although great care is required
to avoid inadvertently counting expanded primitive myeloid
cells as cDC2 when both alleles of IRF8 are deleted. This
may at least partly explain the phenotype of humans with
heterozygous IRF8 T80A mutation, in which an abnormal
population of CD11c+ CD1c– cells appears in place of
CD1c+ cDC2.61 Transcription factor zbtb46 is not required
for development of cDC2 but is up-regulated during differ-
entiation and also appears on mo-DC.143,144
The heterogeneity of transcription factor dependence
observed in mice is consistent with multiple subsets of
cDC2, as recently described in humans.8,9 IRF4, KLF4, LTBR
and MAFB are slightly differentially expressed by cDC2 sub-
sets but RELB and NOTCH2 are uniform across cDC2.
There is no obvious correlation with pre-DC or monocyte
origin; pre-cDC have high expression of both IRF4 and
KLF4 whereas monocytes express comparable levels with DC
of KLF4, MAFB, RELB and NOTCH2 (data from ref. 9).
Functions and role in immunity
Myeloid cDC2 are equipped with a wide range of lectins,
TLRs, NOD-like receptors and RIG-I-like receptors simi-
lar in range to that expressed by monocytes. Human
blood cDC2 respond well to lipopolysaccharide, flagellin,
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poly IC and R848.145 The potential of CD1c and CD1a to
present the glycolipid antigens of mycobacteria and other
pathogens is often overlooked.146 Among the lectins,
CLEC4A (DCIR/CD367), CLEC10A (CD301) CLEC12A
(CD371) and the asialoglycoprotein receptor are highly
expressed. In common with monocytes, TLRs 2, 4, 5, 6
and 8 are present with notable expression of NOD2,
NLRP1, NLRP3 and NAIP (data from ref. 9). Dectin-1
(CLEC7A) and Dectin-2 (CLEC6A) are highly expressed
in tissue cDC2, suggesting a role in fungal recogni-
tion.147,148 DEC205 (CD205; CLEC13B) and macrophage
mannose receptor (CD206; CLEC13D) are variable.95
In contrast with mice, human cDC2 can be stimulated
to become high producers of IL-12 and excellent cross-
presenting cells.20,21,107,108 Their ability to synthesize
IL-12 is greater than that of cDC1 in most conditions
analysed. They secrete IL-23, IL-1, tumour necrosis fac-
tor-a (TNF-a), IL-8 and IL-10 but are consistently low in
the secretion of type III interferon.109,149 In vitro, human
cDC2 are potent in the activation of Th1, Th2, Th17 and
CD8+ T cells,109,149,150 suggesting the capacity to promote
a wide range of immune responses in vivo. Subsets of
cDC2 defined by CD5 and other markers differ in their
production of TNF-a, IL-6, IL-10 and IL-23 in response
to TLR ligation.8,140 CD5-high ‘DC-like’ cDC2 are more
active in CCR7-dependent migration, stimulate high naive
T-cell proliferation and preferential priming of Th2,
Th17, Th22 and regulatory T cells. ‘Monocyte-like’ cDC2
with lower CD5 are less active in proliferation assays and
produce mainly Th1 cells.8 Subsets of cDC2 specializing
in Th2 or Th17 responses are dependent upon IRF4 or
KLF4, respectively,58,60 but this has not been corroborated
in humans.
Langerhans cells
Phenotype and distribution
Langerhans cells are specialized DC that inhabit the basal
epidermis and other stratified squamous epithelia. They
express the C-type lectin langerin and the invariant MHC
class I molecule CD1a. The close integration of LC within
the epithelial layer is mediated by E-Cadherin, EpCAM
(TROP1) TROP2, AXL and tight junction proteins claudin,
occludin and ZO-1.151,152 In common with myeloid cDC2
they express high levels of FceR1 and CD39 (ATPase).
Myeloid cDC2 spontaneously express a low level of lan-
gerin in many sites, but the high expression of langerin,
CD1a and EpCAM, together with lower expression of
CD11c, CD11b and CD13 by LC, is usually sufficient to
separate them clearly.22,131 Care must be taken not to
include cDC1 and LC together as both show lower CD11c
expression than cDC2. This has led to controversy about
the relationship of LC with the cDC1 lineage.111,153
Although LC are distinct from cDC1 ontogenetically,111 it
is clear that they do have functional cross-presentation
capacity154,155 and high MHC class I-related gene expres-
sion in humans.111 LC migrate to skin-draining lymph
nodes, where they appear in the T-cell areas expressing lan-
gerin, CD1a and CD1c. EpCAM and other epithelial mark-
ers are down-regulated, making it more difficult to
distinguish LC from cDC2 by microscopy, although lan-
gerin is still expressed. Differences between inflamed and
non-inflamed skin-draining nodes156 and between skin-
draining nodes and tonsil22 have been used to highlight the
contribution of migratory LC to nodal DC populations.
Development
Langerhans cells are phylogenetically ancient and share a
primitive origin with tissue macrophages and microglia of
the brain.157 This has led to their classification as ‘macro-
phages’,1 a controversial position given that they epito-
mize the function of myeloid DC that capture antigen,
mature and migrate to lymph nodes.158 Recent lineage
tracing experiments in mice indicate that LC have an
equal claim to DC and macrophage heritage by virtue of
unique dual expression of ZBTB46 and MAFB.159 Their
development is unique among DC in that once estab-
lished by primitive and fetal liver haematopoiesis, LC are
capable of local self-renewal, independently of the bone
marrow.160 Proliferating human LC were described many
years ago161 and self-renewal may be demonstrated in
humans lacking DC-poiesis due to mutations in GATA2
or IRF862,162 or recipients of limb transplantation.163
Recent data indicate that mucosal LC are more dependent
upon bone-marrow-derived precursors.164
In mice, the establishment of a self-renewing network
is dependent upon PU.1 RUNX3 and ID2 in combination
with locally produced cytokines IL-34, TFG-b and bone
morphogenetic protein 7 (reviewed in ref. 165). The
sequential formation of human fetal LC from myeloid
precursors has been observed in detailed microscopic
studies and ascribed to non-monocyte precursors.166 In
the steady state, the influence of TGF-b, E-cadherin/
b-catenin and the binding of Axl to gas 6 maintains LC
in a quiescent state.151,152,167,168
In postnatal life, local self-renewal restores LC numbers
following chronic or low-grade inflammatory insults.169
However, studies in mice show that severe inflammation
recruits de novo bone-marrow-derived precursors in two
waves; a transient population of classical monocytes fol-
lowed by uncharacterized myeloid precursors that form a
stable self-renewing LC network as inflammation sub-
sides.170,171 Bone marrow transplantation in humans also
results in replacement by donor cells even after non-mye-
loablative treatment and in the absence of overt graft-ver-
sus-host disease.172,173
In vitro models of LC development from CD34+ pro-
genitors, cDC2 and monocytes offer potential routes to
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explain the repopulation of LC in vivo, following severe
inflammation.174 Purified monocytes, contrary to early
reports, do not make LC efficiently with GM-CSF and TGF-
b,175 but require additional notch signals to down-regulate
a KLF4-dependent pathway of differentiation.176–178
Myeloid cDC2, however, rapidly up-regulate langerin to
high levels and form Birbeck granules with GM-CSF or
TSLP and TGF-b or BMP7.133,134,179 In vivo evidence for
these two pathways has recently been reported in the home-
ostasis of mucosal LC164 but direct evidence is lacking in
humans.
Functions and role in immunity
When the skin becomes inflamed, local production of
TNF-a and IL-1b stimulate LC to lose their connections
with the surrounding epithelium and migrate across the
basement membrane into the afferent lymphatics.
Although LC were the primary model of migratory mye-
loid DC, their non-redundant function in immunity has
been surprisingly difficult to pin down. In humans, they
can be matured into potent cross-presenting DC with
high IL-15 production and the ability to present
mycobacterial glycolipid antigens and stimulate CD8 T
cells.154,155 Transgenic expression of human CD1a on
murine LC licensed them for presentation of lipid anti-
gens to Th17 and Th22 cells. resulting in skin inflamma-
tion.180 However, it has also been reported that LC lack
critical TLRs145 and can induce regulatory T cells and
IL-22 production through CD1a-restricted antigens to
autologous T cells.181 Overall, the role of LC has been
summarized as maintaining epidermal health and toler-
ance to commensals, while retaining the ability to
respond to selected intracellular pathogens and viruses
under inflammatory conditions.182
Monocyte-derived inflammatory DC
Phenotype and distribution
The term ‘inflammatory dendritic cell’ has come to be
defined as monocyte-derived DC (mo-DC) that appear in
inflammation. Ontogeny-based nomenclature would
require that the term monocyte-derived is retained, since
DC lineage cells may also be recruited in inflammation.183
In mice, inflammatory mo-DC were originally demon-
strated in leishmaniasis but have now been recognized in
other infections and inflammatory settings (reviewed in
refs. 184,185). In humans, inflammatory myeloid cells have
been reported in several settings including eczema,186 pso-
riasis,187,188 skin sensitization,189 allergic rhinitis,190 coeliac
disease,191 inflammatory bowel disease,192,193 synovitis and
peritonitis.24,194 Kinetics, surface markers, gene expression
and even direct labelling suggest that monocyte-
derived cells dominate these populations. Considerable
heterogeneity is observed with no clear consensus on the
use of the terms monocyte, macrophage or DC to describe
inflammatory monocyte-derived cells (Table 2). Inflamma-
tory monocytes retain expression of CD13, CD33, CD11b,
CD11c and CD172a and may show recent evidence of
recruitment from monocytes by their expression of
S100A8/9 and CCR2.190,194 In humans, monocytes express
CD11c and MHC class II so these markers are not helpful
in separating monocytes from DC. Evidence of DC differ-
entiation is supported by the expression of CD1c, CD1a,
FceR1, IRF4 and ZBTB46. Inflammatory mo-DC have also
been described to express CD206 and CD209, but retained
expression of CD14 and co-expression of CD16, CD163
and FXIIIA, together with lack of CD1c, CD1a and FceR1,
are more consistent with a phenotype usually described as
macrophage-like. In two studies, where it was possible to
characterize dual populations of DC-like and macrophage-
like cells, the key properties linked to DC phenotype were
CD11c, CD1c, FceR1, CD206, IRF4 and allo-stimulation.
CD14 was variable but CD16 and CD163 were nega-
tive.24,194 Although gene expression showed subset-
restricted patterns, there were many shared transcripts
between populations designated as mo-DC and those
described as monocyte-derived macrophages.
Development and functions in immunity
Populations of monocyte-derived cells exist in human
steady-state tissues, including the skin,13 lung14–16 and
intestine.17 It is not known if this is a distinct mechanism
of recruitment or one that is accelerated and activated in
inflammation. During inflammation, monocyte-derived
cells expand resident populations many-fold.189–194 Pre-
vailing models suggest that monocyte-derived cells func-
tion mainly at a site of inflammation rather than
migrating to lymph nodes.195 However, mo-DC studied
ex vivo secrete IL-1, TNF-a, IL-12 and IL-23, stimulate
CD4 and CD8 T cells and express CCR7.24,188,194 Although
it is possible to derive potent mo-DC in vitro with GM-
CSF and IL-4 followed by activating stimuli such as
lipopolysaccharide or prostaglandin E2, the use of such
preparations in immunotherapy is declining in favour of
‘naturally-occurring’ DC such as pDC or cDC2 (reviewed
in ref. 196). The disappointing performance of mo-DC in
cancer immunotherapy is being interpreted as due to an
intrinsic lack of biological potency of monocyte-derived
cells.141 However, the in vivo conditions under which mo-
DC form are still poorly replicated by in vitro experiments.
CD16+ non-classical monocytes, SLAN+ DC and
DC4
The CD16+ non-classical monocyte is still considered as a
DC by some authors. In particular, those that express a
carbohydrate modification of the P-selectin glycoprotein
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ligand 1, SLAN (recognized by the antibody M-DC8)
have been identified as ‘SLAN DC’.197 The nomenclature
is confusing however, as others have since used SLAN to
identify a ‘true’ non-classical monocyte population (dis-
tinct from intermediate CD14+ CD16+ cells).198 The sim-
ple facts are that CD16+ monocytes are heterogeneous
and that SLAN expression identifies a subpopulation with
lower CD11b, CD14 and CD36 but higher expression of
CD16. Concerning the question of whether SLAN+ cells
are monocytes or DC, their gene expression is clearly
monocytic.13,198–200 Furthermore, recent human in vivo
and xenograft experiments support the hypothesis that
non-classical monocytes differentiate from classical mono-
cytes by down-regulating inflammatory pathways and
adopting a CX3CR+ CCR2– CD11chi CD11blo pheno-
type.201 However, it should be noted that gene expression
alone does not absolutely exclude an independent origin
of SLAN+ cells from the remainder of CD16+ monocytes
and that SLAN itself was not measured on the output of
cells derived from human classical monocytes in the
adoptive transfer experiments.201
Most recently, single cell RNAseq studies found CD16+
cells among HLA-DR+ lineage-negative (CD3, CD19,
CD56) CD14-negative cells and classified them as ‘DC4’.9
DC4 was described as transcriptomically distinct from
non-classical monocytes, yet it was obtained from the
same CD16+ population that contains non-classical
monocytes, by a slightly different gating route. One of the
drawbacks of transcriptomic clustering is that it is diffi-
cult to relate population frequency back to input cells.
The most likely explanation for DC4 is that is signifies a
subset of CD16+ monocytes. Although it is possible to
‘index’ single cells back to their flow parameter space, the
position of DC4 within the non-classical monocyte gate
was not shown. It is apparent that DC4 has a transcrip-
tional profile reminiscent of SLAN+ cells with lower
CD11b, CD14 and CD36 but higher expression of CD16.
The expression of SLAN itself, a post-translational modi-
fication, was naturally invisible to transcriptomic analysis.
Recent experiments conclude that DC4 and SLAN+ cells
are indeed identical202 but further studies are required to
discover their non-redundant roles in immunity.
Conclusion
In summary, human DC arise by a dedicated pathway of
lympho-myeloid haematopoiesis and differentiate into
specialized subsets under the influence of lineage-specific
transcription factors, notably IRF8 and IRF4. Plasmacy-
toid DC and cDC1 are the most specialized with relatively
restricted roles in sensing nucleic acid and responding by
interferon production. Cross-presentation to CD8 cells is
not restricted to cDC1 but can be performed by cDC2
and mo-DC with appropriate activation. The wide range
of CD4+ T-cell priming capacity by cDC2 is likely to
reflect heterogeneity within this population. Single-cell
experiments have clarified that pDC and pre-cDC have
often been previously analysed as a mixed population.
DC subset specialization increases the range and flexibility
of immune responses through mechanisms that are rela-
tively conserved across mammalian species. This knowl-
edge has become essential in translating murine
immunology to human pathology and continues to
expand the therapeutic horizon of DC in medicine.
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